Handelsman Y, et al. – In this multinational, active-controlled, parallel-group, phase 3b trial, researchers assessed the safety and effectiveness of an intensification strategy of early triple combination therapy with dapagliflozin (DAPA) plus saxagliptin (SAXA) vs a dual therapy strategy with sitagliptin (SITA) in patients with type 2 diabetes inadequately controlled on metformin (MET) monotherapy. Study participants included 461 adults with glycated hemoglobin (HbA_1c) levels of 8% to 10.5% (64–91 mmol/mol) who were randomized to either DAPA plus SAXA or SITA, added to MET, for a 26-week double-blind treatment period and an extension 26-week blinded treatment period. According to results, early intensification to triple therapy with DAPA plus SAXA resulted in better, more durable glycemic control than the addition of only SITA (dual therapy) in patients with high levels of HbA_1c, uncontrolled on MET monotherapy.